Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Breast Cancer Clinical Trials

A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found (296) clinical trials

Merestinib on Bone Metastases in Subjects With Breast Cancer

This is an open label, pharmacodynamics, intrapatient dose escalation phase 1B study.

Phase

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919

Phase

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Once subjects are determined eligible, white blood cells (lymphocytes) are collected via leukapheresis procedure approximately 3 to 4 weeks prior to the first BATs infusion. The white blood cells, specifically T cells, are then mixed with two proteins in order to activate the cells to multiply. After approximately 14 days …

Phase

First-in-human Study of DS-1062a for Advanced Solid Tumors

The dosage strength will change during the study but all participants will receive the same study drug. So the study is not a true 2-arm study, it is a 2-part study. In both parts, participants with pathologically documented unresectable advanced NSCLC who have been refractory to or relapsed from standard …

Phase

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of PI3Kbeta inhibitor AZD8186 (AZD8186) when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. II. To assess the safety and tolerability of AZD8186 when administered in combination …

Phase

Effect of Statin Use on Aldosterone Secretion

In order to provide additional evidence regarding the effect of statin therapy on aldosterone levels, the investigators propose the following randomized, double-blinded, placebo controlled protocol in relatively healthy volunteers. The investigators will evaluate aldosterone and cortisol production in response to an angiotensin II infusion under the following test conditions: 1) …

Phase

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

This is phase 1 trial of LTLD with MR-HIFU induced heating in children and young adults with relapsed/refractory solid tumors. Part A of the trial will be a traditional dose escalation study to determine the pediatric MTD/RP2D of LTLD combined with MR-HIFU ablation which allows for release of doxorubicin in …

Phase

Testing the Addition of an Anti-cancer Drug M6620 to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative or Estrogen and/or Progesterone Receptor Positive HER2 Negative Breast Cancer

PRIMARY OBJECTIVE: I. To determine the recommended phase 2 dose of twice weekly ATR kinase inhibitor M6620 (M6620) administered concurrently with conventionally fractionated radiation therapy (RT) to the breast/chest wall and regional nodes. SECONDARY OBJECTIVES: I. To describe the nature of toxicity that develops when an ATR inhibitor is administered …

Phase

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

The main objective of the study is to assess whether the combination of ipatasertib and HP (+/- ET) is tolerable, especially in terms of the incidence and severity of diarrhea. For this purpose, up to a total of 25 patients will be enrolled in a staggered manner and evaluated. A …

Phase

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer, lung cancer, bladder cancer, liver cancer, and malignant melanoma. Patients must be positive …

Phase